Mogilarta (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide and Telmisartan, the active ingredients in Mogilarta, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for systemic use. They treat hypertension in adult patients.

GNH USA supplies Mogilarta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mogilarta combines an angiotensin II receptor blocker with a thiazide diuretic to manage elevated blood pressure across the hypertension spectrum.

- Essential hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. - Secondary hypertension: assists in blood‑pressure control when underlying causes are being treated. - Isolated systolic hypertension: improves pulse pressure in older adults.

Mogilarta may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia, especially with potassium‑sparing agents - Angioedema or severe allergic reaction - Significant hypotension leading to syncope

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function: assess baseline creatinine and eGFR, then monitor periodically. - Electrolytes: check serum potassium and sodium, especially when combined with other diuretics. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant NSAIDs: avoid or monitor renal function closely. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mogilarta can alter the effects of several other medicines; awareness of interaction severity helps guide safe use.

Major Interactions (Avoid): - Aliskiren in diabetic patients: risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: increased lithium levels and toxicity. - Cyclosporine: heightened risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response and affect renal function. - CYP2C9 inhibitors (e.g., fluconazole): can raise telmisartan concentrations. - Antacids containing aluminum or magnesium: may reduce hydrochlorothiazide absorption.